Regulating advanced therapeutic products
On this page
- Advanced therapeutic products
- Canada's regulatory approach for advanced therapeutic products
- How the framework will work
- International harmonization
- Enhanced support for innovators
- Opportunities for comment
- Contact us
Advanced therapeutic products
Advanced therapeutic products (ATPs) are drugs or devices, or any combination of drugs and devices, that our current regulations were not designed to handle because they're so complex or distinct.
Scientific and technological advances are speeding the pace of change in health care. This is leading to innovative health products that are:
- developed at point of care
- manufactured, distributed and used in ways that differ significantly from traditional health products
Canada's regulatory approach for advanced therapeutic products
Legislative provisions introduced in the Food and Drugs Act from June 2019 created a new framework to authorize ATPs.
This framework allows Health Canada to customize regulatory requirements for these products to:
- maintain appropriate, yet flexible, regulatory oversight
- promote innovation in drug and medical device development
- ensure high standards for patient safety, product quality and efficacy and effectiveness
- reduce barriers to bringing ATPs to market in Canada, thus providing access to new, potentially life-changing treatments
We will continue to regulate most drugs and devices within our existing regulatory frameworks. The new framework will provide the ability to authorize ATPs in a flexible and risk-based manner for products that significantly challenge our current system.
How the framework will work
In assessing whether a product may be eligible for the framework, Health Canada will consult with stakeholders and consider factors such as:
- the risks and benefits associated with the product, and steps available to manage and control these risks
- how different the product is from already approved drugs or devices
- whether there are other appropriate controls in place, for example through provincial and territorial legislation
Regulating products in the ATP framework will require consultation and collaboration with:
- those directly involved in the development and use of these products, such as:
- hospitals and clinics
- health system partners including:
- health technology assessment bodies
- provincial and territorial representatives
- international regulators
This will allow for a transparent process and the development of tailored requirements to allow access to the product or class of products in Canada. Furthermore, early alignment and coordination with these groups supports access to and adoption of these products within the health care system.
If a product or class of products qualifies for the ATP framework, the Minister of Health will add it to Schedule G in the Food and Drugs Act. Once an item is added to Schedule G, there are 2 ways to access the tailored ATP pathways:
- a licensing scheme that requires authorization from Health Canada before marketing a product in Canada
- an order of permission where conditions must be met before the product can be put on the Canadian market
In addition to customized authorization requirements, under the licensing scheme, the Minister can impose terms and conditions to each product licence. These terms and conditions:
- may allow earlier access to promising therapies
- will ensure appropriate oversight to mitigate risks
Health Canada will tailor an oversight framework for post-market obligations for each ATP.
Health Canada, in collaboration with the sponsor(s), will monitor the safety and effectiveness of ATPs. We can amend tailored requirements and terms and conditions as we gain new information and experience. We can suspend or cancel licences if deemed necessary.
Lastly, Health Canada can amend existing regulations or develop new regulations for the ATP after we have gathered enough experience with how we need to regulate the ATP.
Health Canada recognizes the importance of harmonizing requirements internationally, and has the ability to leverage what has worked well in other jurisdictions using the ATP framework.
Enhanced support for innovators
Innovators and industry will need guidance to navigate the new framework. To serve this need, we plan to offer a specialized "concierge" service for the ATP framework. Users will have a point of contact for direct, well-informed interactions with a Health Canada representative for ATP products through this enhanced level of service.
Health Canada takes an early and collaborative approach to stakeholder engagement to identify potential ATPs.
The department relies on stakeholder input to help evaluate a number of technology areas as potential candidates for the ATP framework. The department:
- uses environmental scans and stakeholder feedback to identify candidates
- consults with key internal and external partners to evaluate candidates against the ATP criteria
The first 2 products to be developed as ATPs are:
- adaptive machine learning-enabled medical devices
- medical devices that will undergo modifications by learning from new data
- fecal microbiota therapy
- the transfer of bacteria into a patient's intestinal tract to establish a healthy microbial community to help fight antimicrobial resistance, such as when treating recurrent C. difficile infections
Health Canada is committed to transparency and openness to strengthen trust in our regulatory decisions. Health Canada will apply these principles to ATPs as appropriate. For example, stakeholders will continue to:
- be involved in proposing ATP candidates
- inform the tailored regulatory pathway that is developed for each ATP
Health Canada is committed to communicating information concerning ATPs to the public. The most up-to-date information will be available on this web page.
Opportunities for comment
Health Canada will publish an ATP Guidance document for stakeholder comment in spring 2022.
The department will engage stakeholders as it develops the tailored requirements for the first 2 ATPs.
We encourage stakeholders to contact us with questions and feedback regarding ATPs.
Biologic and Radiopharmaceutical Drugs Directorate
Health Products and Food Branch
Report a problem or mistake on this page
- Date modified: